ReviewAdvances in therapy2017
Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.
Review in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Effects of Ripasudil Hydrochloride Hydrate-Brimonidine Tartrate Fixed-Dose Combination Using Rho Kinase Inhibitor and Alpha2 Adrenergic Receptor Agonist on Aqueous Column in the Episcleral Vein: A Randomized, Double-Masked, Crossover Clinical Trial (ROCK Alpha-Aqua Study).Journal of clinical medicine · 2026Article
- Rho Kinase (ROCK) Inhibitors in the Treatment of Glaucoma and Glaucoma Surgery: A Systematic Review of Early to Late Phase Clinical Trials.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Revolution in glaucoma treatment: a review elucidating canaloplasty and gonioscopy-assisted transluminal trabeculotomy as modern surgical alternatives.Frontiers in medicine · 2025Review
- Human Anterior Segment Perfusion Organ Culture.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Lasamide Containing Sulfonylpiperazines as Effective Agents for the Management of Glaucoma Associated Symptoms.ChemMedChem · 2024Article
- Five-Year Outcomes of Single Trabecular Microbypass Stent (iStentOphthalmology and therapy · 2023Article
- Novel discovery of a lymphatic bridge connecting Schlemm's canal to limbal and conjunctival lymphatic pathway.The ocular surface · 2023Article
- Clinical outcomes of canaloplasty via an ab-interno surgical technique using the iTrack device: a narrative review.International ophthalmology · 2023Review
- Isolation and Culture of Vascular Distal Outflow Pathway (VDOP) Cells From Human Donor Eyes.Current protocols · 2022Article
- Schlemm's canal: the outflow 'vessel'.Acta ophthalmologica · 2022Review
- Evaluation of different OCT systems in quantitative imaging of human Schlemm's canal.Scientific reports · 2022Article
- The Application of Nitric Oxide for Ocular Hypertension Treatment.Molecules (Basel, Switzerland) · 2021Review
- Isolation and characterization of novel primary cells from the human distal outflow pathway.Scientific reports · 2021Article
- Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma.Small (Weinheim an der Bergstrasse, Germany) · 2020Article
- Observational
- Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.Annals of medicine · 2020Article
- Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?Translational vision science & technology · 2020Review
- Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles.Journal of biomedical materials research. Part A · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schlemm's canal (SC) is a unique, complex vascular structure responsible for maintaining fluid homeostasis within the anterior segment of the eye by draining the excess of aqueous humour. In glaucoma, a heterogeneous group of eye disorders afflicting approximately 60 million individuals worldwide, the normal outflow of aqueous humour into SC is progressively hindered, leading to a gradual increase in outflow resistance, which gradually results in elevated intraocular pressure (IOP). By and large available antiglaucoma therapies do not target the site of the pathology (SC), but rather aim to decrease IOP by other mechanisms, either reducing aqueous production or by diverting aqueous flow through the unconventional outflow system. The present review first outlines our current understanding on the functional anatomy of SC. It then summarizes existing research on SC cell properties; first in the context of their role in glaucoma development/progression and then as a target of novel and emerging antiglaucoma therapies. Evidence from ongoing research efforts to develop effective antiglaucoma therapies targeting SC suggests that this could become a promising site of future therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.